Nephrogenic Diabetes Insipidus
A condition where the kidneys don't respond to the hormone that tells them to hold onto water, leading to excessive urination and extreme thirst.
Emergency Management: Severe hypernatremic dehydration. Treatment requires gradual lowering of serum sodium using hypotonic fluids (e.g., 5% Dextrose in Water or 0.45% Saline). Sodium must not be lowered faster than 0.5 mEq/L/hour to prevent cerebral edema.
Nephrogenic Diabetes Insipidus (NDI) is a renal tubular disorder characterized by the inability of the kidneys to concentrate urine in response to antidiuretic hormone (ADH, or vasopressin). This leads to the excretion of large volumes of dilute urine (polyuria) and extreme thirst (polydipsia).
Detailed Overview
Unlike central diabetes insipidus where there is a lack of ADH production, NDI involves a failure of the renal collecting ducts to respond to adequate or elevated levels of ADH. NDI can be hereditary, presenting in infancy, or acquired, most commonly due to lithium toxicity, hypercalcemia, or hypokalemia. If free water intake cannot match output, severe hypernatremic dehydration and hyperosmolar states ensue. Treatment focuses on correcting the underlying cause and paradoxically using thiazide diuretics to reduce polyuria.
Epidemiology & Demographics
Congenital NDI is rare, affecting roughly 1 in 250,000 live births (mostly males). Acquired NDI is much more common, notably affecting up to 20-40% of patients on chronic Lithium therapy.
Etiological Mechanism
Hereditary NDI is predominantly X-linked recessive due to mutations in the AVPR2 gene (encoding the V2 receptor). Less commonly, it is autosomal recessive/dominant due to mutations in the AQP2 gene (aquaporin-2 water channel). Acquired causes include Lithium use, Demeclocycline, hypercalcemia, severe hypokalemia, and chronic tubulointerstitial diseases.
Primary Causes
Lithium toxicity
Hypercalcemia
Hypokalemia
AVPR2 gene mutation (X-linked)
AQP2 gene mutation
Normally, ADH binds to the V2 receptor on the basolateral membrane of the principal cells in the late distal tubule and collecting duct. This activates adenylyl cyclase, raising intracellular cAMP, which triggers the insertion of Aquaporin-2 (AQP2) water channels into the apical membrane, allowing water reabsorption. In NDI, this pathway is disrupted. In genetic forms, the V2 receptor or AQP2 is defective. In Lithium-induced NDI, Lithium inhibits adenylyl cyclase and glycogen synthase kinase 3 (GSK3), preventing AQP2 insertion. The collecting ducts remain impermeable to water, resulting in massive loss of free water, leading to plasma hyperosmolality and hypernatremia.
Diagnostic Criteria & Guidelines
Diagnosis is confirmed by the Water Deprivation Test. Patient is deprived of water until plasma osmolality reaches >295 mOsm/kg. In NDI, urine remains dilute (urine osmolality < 300 mOsm/kg). Exogenous Desmopressin (DDAVP) is then administered; in NDI, there is no significant increase in urine osmolality (<50% increase), distinguishing it from central DI.
For acquired NDI, correct the underlying cause: discontinue Lithium if psychiatrically feasible, correct hypercalcemia or hypokalemia. Dietary sodium restriction (<2 grams/day) and low-protein diet reduce solute load, thereby decreasing obligate water excretion. Hydrochlorothiazide (HCTZ) 25-50 mg PO daily is the pharmacological cornerstone. It induces a mild volume depletion, which enhances proximal tubule reabsorption of sodium and water, reducing the volume of filtrate reaching the collecting duct.
Second-Line & Adjunctive Therapy
Amiloride (5-10 mg PO daily) is particularly useful for Lithium-induced NDI because it blocks the ENaC channels in the collecting duct, preventing Lithium from entering the principal cells. NSAIDs (Indomethacin 50 mg PO TID) inhibit renal prostaglandin synthesis (prostaglandins antagonize ADH action), increasing urinary concentrating ability.
Surgical & Procedural Management
None indicated.
Patient Counseling & Advice
Educate the patient that their kidneys cannot hold onto water. They must never be restricted from drinking water. In case of illness with vomiting or diarrhea, they are at extreme risk of rapid dehydration and must seek emergency medical care immediately.
Follow-Up & Monitoring Schedule
Regular monitoring of serum electrolytes (sodium, potassium) and renal function, especially since treatment involves diuretics and NSAIDs.
Preventive Strategies
For patients on Lithium, maintain the lowest effective dose, monitor drug levels regularly, and avoid concomitant dehydration.
With free access to water and appropriate medical management, patients can lead a normal life. In congenital NDI, early diagnosis is crucial to prevent neurological damage from hypernatremia.